Welcome to our dedicated page for TNL Mediagene SEC filings (Ticker: TNMG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNL Mediagene (TNMG) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. TNL Mediagene files reports on Form 6-K under the Securities Exchange Act of 1934, furnishing press releases, transaction documents and corporate updates that explain key developments in its digital media and data business.
Recent Form 6-K filings include explanations of Nasdaq listing status and compliance with the minimum bid price rule, details of a 1-for-20 share consolidation of ordinary shares, and descriptions of financing arrangements such as senior convertible notes and an equity line of credit. Other filings furnish press releases related to unaudited financial results, annual general meeting outcomes, amendments to corporate documents, and information about board changes and director appointments.
For investors analyzing TNL Mediagene’s capital structure, these filings outline terms of convertible notes, warrants and equity purchase agreements, as well as the company’s interactions with the Nasdaq Hearings Panel. They also incorporate press releases that describe operational initiatives, including AI-driven content infrastructure, content licensing partnerships and business unit performance, giving additional context to the company’s strategic direction.
On Stock Titan, each filing is accompanied by AI-powered summaries designed to highlight the main points of long-form documents, helping readers quickly understand what a particular Form 6-K covers and why it may matter for TNMG stock. Users can monitor new filings as they are retrieved from EDGAR, review historical disclosures, and connect regulatory information with the company’s broader narrative in digital media, advertising technology and e-commerce.
TNL Mediagene has notified investors that, as a foreign private issuer incorporated in the Cayman Islands, it is using Nasdaq’s home country rule exemption under Rule 5615(a)(3). This allows the company to follow Cayman corporate practices instead of certain Nasdaq shareholder-approval rules.
Specifically, the company will not follow Nasdaq Rules 5635(a), (b), (c) and (d), which in the U.S. normally require shareholder votes before major share issuances for acquisitions, changes of control, equity compensation plans, or private issuances of 20% or more of voting power below a defined minimum price. The company states that aside from these and previously disclosed home country practices, its governance is generally aligned with typical U.S. Nasdaq-listed companies.
TNL Mediagene reported that Nasdaq has notified the company it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company’s Form 20-F for the period ended December 31, 2025 showed stockholders’ equity of $918,088, below this threshold.
Nasdaq also determined the company does not meet the alternative standards based on market value of listed securities or net income from continuing operations. TNL Mediagene has until June 22, 2026 to submit a compliance plan and may receive up to 180 calendar days from the May 6, 2026 deficiency letter to regain compliance if its plan is accepted. Management is evaluating options and intends to submit the plan while the company’s shares remain listed during this process.
TNL Mediagene reported that Nasdaq has notified the company it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company’s Form 20-F for the period ended December 31, 2025 showed stockholders’ equity of $918,088, below this threshold.
Nasdaq also determined the company does not meet the alternative standards based on market value of listed securities or net income from continuing operations. TNL Mediagene has until June 22, 2026 to submit a compliance plan and may receive up to 180 calendar days from the May 6, 2026 deficiency letter to regain compliance if its plan is accepted. Management is evaluating options and intends to submit the plan while the company’s shares remain listed during this process.
TNL Mediagene reported FY2025 revenue of $45.0 million, below the preliminary outlook of $49.1 million, mainly due to softer performance and project delays in its digital studio and digital media businesses and consolidation adjustments.
The digital studio segment remained the core focus and largest unit, generating $18.7 million, or 41.4% of total revenue, supported by long-term clients in Japan and public-sector contracts in Taiwan. The company is integrating AI into content production and launched AI-assisted products in its digital studio business in late 2025.
Net loss narrowed significantly to $44.6 million in FY2025 from $85.0 million in FY2024, helped by the absence of a prior-year $38.2 million non-cash listing expense, lower professional fees and finance costs. However, results included a large $39.2 million non-cash impairment of goodwill and intangibles tied to its Japan Mediagene business after projections were revised downward.
The company’s liquidity is tight, with $1.9 million in cash and cash equivalents at December 31, 2025, and its audited financials carry a going concern emphasis, stating it needs additional financing to fund operations beyond FY2026. Management drew on an equity line of credit, issued equity and convertible debt, and is exploring further funding options.
TNL Mediagene also disclosed that internal control over financial reporting was not effective as of year-end due to three material weaknesses still under remediation. A leadership realignment and FY2026 strategic initiatives aim to sharpen focus on digital studio services, content commerce and AI-powered products alongside ongoing cost efficiency measures.
TNL Mediagene reported FY2025 revenue of $45.0 million, below the preliminary outlook of $49.1 million, mainly due to softer performance and project delays in its digital studio and digital media businesses and consolidation adjustments.
The digital studio segment remained the core focus and largest unit, generating $18.7 million, or 41.4% of total revenue, supported by long-term clients in Japan and public-sector contracts in Taiwan. The company is integrating AI into content production and launched AI-assisted products in its digital studio business in late 2025.
Net loss narrowed significantly to $44.6 million in FY2025 from $85.0 million in FY2024, helped by the absence of a prior-year $38.2 million non-cash listing expense, lower professional fees and finance costs. However, results included a large $39.2 million non-cash impairment of goodwill and intangibles tied to its Japan Mediagene business after projections were revised downward.
The company’s liquidity is tight, with $1.9 million in cash and cash equivalents at December 31, 2025, and its audited financials carry a going concern emphasis, stating it needs additional financing to fund operations beyond FY2026. Management drew on an equity line of credit, issued equity and convertible debt, and is exploring further funding options.
TNL Mediagene also disclosed that internal control over financial reporting was not effective as of year-end due to three material weaknesses still under remediation. A leadership realignment and FY2026 strategic initiatives aim to sharpen focus on digital studio services, content commerce and AI-powered products alongside ongoing cost efficiency measures.
TNL Mediagene files its annual Form 20-F, highlighting severe financial stress and a going concern warning. For the year ended December 31, 2025 it recorded a loss from operations of approximately $49.6 million, operating cash outflow of $4.9 million, negative working capital of $17.5 million and an accumulated deficit of $161.8 million.
The company relies on equity and debt financings, raising $1.9 million via Tumim ELOC shares, $2.2 million via PIPE shares and issuing a $1.5 million Second Note in 2025, alongside about $3.9 million in loan facilities. It also recognized a $39.2 million impairment on intangibles, including fully writing off $25.5 million of Mediagene goodwill, while carrying remaining intangibles of $24.3 million and goodwill of $8.7 million as of December 31, 2025.
The report underscores heavy dependence on digital advertising in Japan and Taiwan, traffic from platforms such as Google, and exposure to structural shifts from AI-driven search and content discovery. It also details significant technology, data privacy, AI, third-party license, and infrastructure risks. As of December 31, 2025, there were 2,556,405 ordinary shares outstanding following a 1‑for‑20 reverse share split in December 2025.
TNL Mediagene announced a leadership realignment and 2026 strategic plan focused on execution, AI and higher-margin services. Motoko Imada becomes Chief Executive Officer, retaining her Chief Operating Officer role and taking full control of operations, P&L, budgets and a company-wide business and cost review. Former CEO Joey Chung becomes President, leading corporate development, strategic transactions, partnerships, capital markets work and investor relations. CTO Richard Lee now also heads Research and Development to build and commercialize AI and strategic technology products, while General Counsel TJ Park is promoted to Chief Corporate Affairs Officer. Co‑founder Hiroto Kobayashi joins the Board, filling a vacancy. For 2026, the company targets organic revenue growth, positive EBITDA, lower SG&A as a share of revenue, an accelerated pivot toward digital studio services, content commerce and AI-powered products, and a portfolio review that may lead to divestitures, downsizing or closure of underperforming media brands.
TNL Mediagene filed a resale prospectus registering 1,600,354 ordinary shares, plus 145,844 warrants and 145,844 ordinary shares issuable upon exercise of those warrants, for resale by specified selling securityholders.
The filing covers resales by 3i (including up to 1,250,000 shares relating to a $1,666,667 second convertible note dated December 8, 2025, up to 300,354 PIPE shares issued to 2025 PIPE investors, and up to 50,000 vendor shares. The prospectus states the company will not receive proceeds from the resale by selling securityholders; the 3i warrants are exercisable for cash when a registration statement is effective and adjusted after a December 22, 2025 share consolidation.
TNL Mediagene has filed a Form F-1 registration statement to register the resale of 1,600,354 ordinary shares, 145,844 warrants and 145,844 ordinary shares underlying those warrants. The filing covers resale by multiple selling securityholders, including 3i, LP, certain PIPE investors and service‑provider vendors.
The registration permits 3i to resell up to 1,250,000 ordinary shares (which may be issued upon conversion of a senior convertible note), up to 145,844 warrants and related underlying shares, up to 300,354 PIPE shares, and up to 50,000 vendor shares. The company states it will not receive proceeds from those resales; Tumim ELOC purchases remain a separate private purchase mechanism through which the company may receive proceeds.
TNL MEDIAGENE disclosed that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC beneficially own 171,113 ordinary shares, representing 6.3% of the company’s ordinary share class as of the event date.
The Goldman Sachs entities report shared voting and dispositive power over all 171,113 shares and no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of TNL MEDIAGENE.
TNL Mediagene has regained compliance with Nasdaq’s minimum bid price requirement, allowing its shares to remain listed on the Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) after the closing bid price of its ordinary shares stayed at $1.00 per share or higher for fifteen consecutive trading days from December 23, 2025 to January 14, 2026.
At the same time, Nasdaq’s Hearings Panel imposed a one-year Discretionary Panel Monitor starting January 20, 2026. During this period, if the company fails any continued listing standard, it will not receive extra time or a cure period; instead, Nasdaq staff will issue a delisting determination, though the company may request a new hearing.